Telix Pharmaceuticals

TLXNasdaq Australia Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$3.195 B

$9.43 -2.48%

Close of 6 Nov 2026

As of 6 Nov 2026, Telix Pharmaceuticals (TLX) has a market capitalization of $3.19B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

338,777,049

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#72Dyne TherapeuticsDYN$3.25B
#73Viridian TherapeuticsVRDN$3.24B
#74Telix PharmaceuticalsTLX$3.19B
#75Bausch Health CompaniesBHC$2.99B
#76IDEAYA BiosciencesIDYA$2.97B

Insiders buying

All insider buying →

One open-market purchase by officers and directors of Telix Pharmaceuticals, worth $20.0K. Grants and option exercises are excluded.

Darren Charlton SmithGroup Chief Financial Officer$20.0K
2,071 shares at $9.66 on 7 Sept 2026 · filed 14 Sept 2026

What if Telix Pharmaceuticals were worth as much as…

Open the what-if tool →

Gold $28.2T

$83,349.43

Per share 8,839× higher

Bitcoin $1.53T

$4,509.89

Per share 478× higher

Apple $5.02T

$14,805.56

Per share 1,570× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for Telix Pharmaceuticals are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.